CD1d belongs to a group of nonclassical antigen-presenting molecules that present glycolipid antigens and thereby activate natural killer T (NKT) cells, a subset of bifunctional T cells. Little is known so far regarding the expression and physiologic regulation of CD1d. Here we show that all-trans-retinoic acid (RA), the active metabolite of vitamin A, rapidly (1 hr after treatment) increases CD1d mRNA in human and rodent monocytic cells at a physiologic dose (10 nM). The induction is RA specific and RA receptor (RAR) dependent—RA and an RARα agonist, Am580, both had a pronounced positive effect, whereas the addition of RARα antagonist partially blocked the increase in CD1d mRNA induced by RA and Am580. The induction was also completely blocked by the presence of actinomycin D. A putative RA-response element was identified in the distal 5′ flanking region of the CD1d gene, which binds nuclear retinoid receptors and was responsive to RA in both gel mobility shift assay and transient transfection assay in THP-1 cells. These results further confirmed the transcriptional regulation of RA in CD1d gene expression. Moreover, RA significantly increased α-galactosylceramide-induced spleen cell proliferation. These studies together provide evidence for a previously unknown mechanism of CD1d gene expression regulation by RA and suggest that RA is a significant modulator of NKT cell activation.
Get full access to this article
View all access options for this article.
References
1.
Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol22:817–890, 2004.
2.
Skold M, Xiong X, Illarionov PA, Besra GS, Behar SM. Interplay of cytokines and microbial signals in regulation of CD1d expression and NKT cell activation. J Immunol175:3584–3593, 2005.
3.
Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest114:1379–1388, 2004.
4.
Skold M, Behar SM. Role of CD1d-restricted NKT cells in microbial immunity. Infect Immun71:5447–5455, 2003.
5.
Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, Ho DD, Tsuji M, Kawahara K, Wong CH, Kronenberg M. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature434:520–525, 2005.
6.
Koch M, Stronge VS, Shepherd D, Gadola SD, Mathew B, Ritter G, Fersht AR, Besra GS, Schmidt RR, Jones EY, Cerundolo V. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol6:819–826, 2005.
7.
Zajonc DM, Cantu C 3rd, Mattner J, Zhou D, Savage PB, Bendelac A, Wilson IA, Teyton L. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol6:810–818, 2005.
8.
Morita M, Motoki K, Akimoto K, Natori T, Sakai T, Sawa E, Yamaji K, Koezuka Y, Kobayashi E, Fukushima H. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem38:2176–2187, 1995.
9.
Ross AC. Vitamin A, retinoids and immune responses. In: Livrea MA, Ed. Vitamin A and Retinoids: An update of biological aspects and clinical application. Basel, Switzerland: Birkauser Verlag, pp83–96, 2000.
10.
Cui D, Moldoveanu Z, Stephensen CB. High-level dietary vitamin A enhances T-helper type 2 cytokine production and secretory immunoglobulin A response to influenza A virus infection in BALB/c mice. J Nutr130:1132–1139, 2000.
11.
DeCicco KL, Youngdahl JD, Ross AC. All-trans-retinoic acid and polyriboinosinic: polyribocytidylic acid in combination potentiate specific antibody production and cell-mediated immunity. Immunology104:341–348, 2001.
12.
Glasziou PP, Mackerras DE. Vitamin A supplementation in infectious diseases: a meta-analysis. BMJ306:366–370, 1993.
13.
Ma Y, Chen Q, Ross AC. Retinoic acid and polyriboinosinic: polyribocytidylic acid stimulate robust anti-tetanus antibody production while differentially regulating type 1/type 2 cytokines and lymphocyte populations. J Immunol174:7961–7969, 2005.
14.
Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. Immunity21: 527–538, 2004.
15.
Seguin-Devaux C, Hanriot D, Dailloux M, Latger-Cannard V, Zannad F, Mertes PM, Longrois D, Devaux Y. Retinoic acid amplifies the host immune response to LPS through increased T lymphocytes number and LPS binding protein expression. Mol Cell Endocrinol245:67–76, 2005.
16.
Zhao Z, Ross AC. Retinoic acid repletion restores the number of leukocytes and their subsets and stimulates natural cytotoxicity in vitamin A-deficient rats. J Nutr125:2064–2073, 1995.
17.
Chen Q, Ross AC. Vitamin A and immune function: retinoic acid modulates population dynamics in antigen receptor and CD38-stimulated splenic B cells. Proc Natl Acad Sci U S A102:14142–14149, 2005.
Gaboli M, Gandini D, Delva L, Wang ZG, Pandolfi PP. Acute promyelocytic leukemia as a model for cross-talk between interferon and retinoic acid pathways: from molecular biology to clinical applications. Leuk Lymphoma30:11–22, 1998.
20.
Chen Q, Ross AC. Retinoic acid regulates cell cycle progression and cell differentiation in human monocytic THP-1 cells. Exp Cell Res297: 68–81, 2004.
21.
Altucci L, Gronemeyer H. Retinoids and TRAIL: two cooperating actors to fight against cancer. Vitam Horm67:319–345, 2004.
22.
Mark M, Ghyselinck NB, Chambon P. Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annu Rev Pharmacol Toxicol46:451–480, 2006.
23.
Evans TR, Kaye SB. Retinoids: present role and future potential. Br J Cancer80:1–8, 1999.
24.
Nagy L, Thomazy VA, Heyman RA, Davies PJ. Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ5:11–19, 1998.
25.
Chen Q, Ma Y, Ross AC. Opposing cytokine-specific effects of all trans-retinoic acid on the activation and expression of signal transducer and activator of transcription (STAT)-1 in THP-1 cells. Immunology107:199–208, 2002.
26.
James SY, Williams MA, Newland AC, Colston KW. Leukemia cell differentiation: cellular and molecular interactions of retinoids and vitamin D. Gen Pharmacol32:143–154, 1999.
27.
Pramanik R, Asplin JR, Lindeman C, Favus MJ, Bai S, Coe FL. Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells. Cell Immunol232:137–143, 2004.
28.
Geng Y, Laslo P, Barton K, Wang CR. Transcriptional regulation of CD1D1 by Ets family transcription factors. J Immunol175:1022–1029, 2005.
29.
Chen QY, Jackson N. Human CD1D gene has TATA boxless dual promoters: an SP1-binding element determines the function of the proximal promoter. J Immunol172:5512–5521, 2004.
30.
Eckhoff C, Nau H. Identification and quantitation of all-trans- and 13-cis-retinoic acid and 13-cis-4-oxoretinoic acid in human plasma. J Lipid Res31:1445–1454, 1990.
31.
Forestier C, Park SH, Wei D, Benlagha K, Teyton L, Bendelac A. T cell development in mice expressing CD1d directed by a classical MHC class II promoter. J Immunol171:4096–4104, 2003.
32.
Xu H, Chun T, Colmone A, Nguyen H, Wang CR. Expression of CD1d under the control of a MHC class Ia promoter skews the development of NKT cells, but not CD8+ T cells. J Immunol171:4105–4112, 2003.
33.
Zimmer MI, Colmone A, Felio K, Xu H, Ma A, Wang CR. A cell-type specific CD1d expression program modulates invariant NKT cell development and function. J Immunol176:1421–1430, 2006.
34.
Szatmari I, Pap A, Ruhl R, Ma JX, Illarionov PA, Besra GS, Rajnavolgyi E, Dezso B, Nagy L. PPAR-gamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med203:2351–2362, 2006.
35.
Iwata M, Eshima Y, Kagechika H. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol15:1017–1025, 2003.
